Masking macrophage injury sensing via poly I sustained release system reduces inflammation and fibrosis

Keyi Chen1, Xingjian You1, Wei Yu2

  • 1Spine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.

Biomaterials
|November 23, 2025
PubMed

Insights

This study developed a biomaterial (PCL-Poly I) to reduce macrophage activation and injury sensing, effectively suppressing tissue fibrosis development and offering a novel treatment strategy for fibrosis-related conditions.

Area of Science:

  • Biomaterials Science
  • Immunology
  • Regenerative Medicine

Background:

  • Tissue fibrosis is a significant complication following injury, driven by excessive macrophage activity.
  • Macrophage sensing of tissue injury via damage-associated molecular patterns (DAMPs) is critical for their activation and migration.
  • Inhibiting macrophage scavenger receptors (MSR) with polyinosinic acid (Poly I) can reduce activation.

Purpose of the Study:

  • To develop a sustained-release biomaterial incorporating Poly I for treating epidural fibrosis (EF).
  • To investigate the efficacy of Poly I in modulating macrophage responses to tissue injury.
  • To assess the therapeutic potential of PCL-Poly I in suppressing fibroblast activation and EF progression.

Main Methods:

  • Development of an electrospun polycaprolactone (PCL) fibrous membrane incorporating Poly I (PCL-Poly I).
  • In vitro and in vivo studies to evaluate Poly I's effect on macrophage signaling pathways (MSR1/PI3K/AKT/SPP1).
  • Local implantation of PCL-Poly I in an epidural fibrosis model following laminectomy.

Main Results:

  • Poly I effectively masked early macrophage injury sensing by downregulating the MSR1/PI3K/AKT/SPP1 pathway.
  • PCL-Poly I implantation reduced early macrophage aggregation and activation in the EF zone.
  • Fibroblast activation and EF progression were suppressed, with therapeutic effects lasting up to 8 weeks.

Conclusions:

  • Biomaterial-based strategies can effectively modulate immune responses to treat fibrosis.
  • PCL-Poly I offers a novel upstream therapeutic approach for fibrosis-related conditions by targeting early macrophage sensing.
  • This study highlights a promising strategy for managing tissue fibrosis and its complications.